Fate Therapeutics
Highly Engaged Employees
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
12278 Scripps Summit Dr, San Diego, Cali...Phone Number
(858) 875-1800Website
www.fatetherapeutics.comRevenue
$6.5 MillionStock Symbol
FATEIndustry
About Fate Therapeutics
Fate Therapeutics Org Chart
Is Fate Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Fate Therapeutics is spiking on competitors!
Product Launch: Get notified when Fate Therapeutics launches new products
Check if Fate Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Fate Therapeutics
Earning: See what the market has to say on Fate Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Fate Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Fate Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Fate Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Fate Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Fate Therapeutics
Compare insights from companies similar to Fate Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Fate Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Fate Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Fate Therapeutics.
Fate Therapeutics financials insights
Gather financial insights about Fate Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Stock Offering
$40.4M
Debt
$20M
Stock Offering
$32M
Share Placement
$10.3M
Share Placement
$57M
Stock Offering
$42.9M
Grant
$4M
Stock Offering
$143.8M
Stock Offering
$173.1M
Fate Therapeutics Tech Stack
A closer look at the technologies used by Fate Therapeutics
Most Recent Scoops
Fate Therapeutics News & Media
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day dischargeFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced that on August 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 37,300 shares of the Company’s commonFate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical DevelopmentFate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical data from the Company’s off-the-shelf CAR T-cell product candidate, FT819, will be presented at the International Society for Stem Cell Research (ISSCR)
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Fate Therapeutics
Fate Therapeutics, established and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on developing innovative cellular immunotherapies. The company specializes in research and development of treatments for cancer and immune disorders, utilizing advanced cellular technology to create therapeutic solutions.... Read More

